IPSEN S A/S (OTCMKTS:IPSEY) was upgraded by stock analysts at Goldman Sachs Group from a “sell” rating to a “neutral” rating in a research report issued on Tuesday, The Fly reports.
Separately, Credit Suisse Group downgraded shares of IPSEN S A/S from a “neutral” rating to an “underperform” rating in a research report on Monday, October 29th.
OTCMKTS:IPSEY traded up $0.19 on Tuesday, reaching $35.29. 456 shares of the stock traded hands, compared to its average volume of 2,253. The company has a market capitalization of $11.75 billion, a PE ratio of 37.95, a P/E/G ratio of 0.70 and a beta of 0.64. IPSEN S A/S has a 1-year low of $30.43 and a 1-year high of $44.60.
Ipsen SA operates as a pharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Dysport for motor disorders and muscular spasticity.
Featured Article: Float
Receive News & Ratings for IPSEN S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN S A/S and related companies with MarketBeat.com's FREE daily email newsletter.